CLAIMS

What is claimed is:

1. A pharmaceutical composition for use in the treatment of an ocular disease, comprising:

A) a biodegradable polymer matrix, comprising a first biodegradable poly(D,L-lactide-co-glycolide) (PLGA) copolymer, a second biodegradable PLGA copolymer, and a third biodegradable PLGA copolymer; and

B) dexamethasone homogenously dispersed within the polymer matrix; and

wherein the pharmaceutical composition is formulated: for intravitreal administration to a subject's eye; and

formulated to release the dexamethasone for at least about 4 months.

2. Use of a biodegradable polymer matrix, wherein the biodegradable polymer matrix comprises a first biodegradable poly(D,L-lactide-co-glycolide) (PLGA) copolymer, a second biodegradable PLGA copolymer, and a third biodegradable PLGA copolymer, and dexamethasone homogeneously dispersed within the polymer matrix, in the manufacture of a medicament for the treatment of an ocular disease, wherein the medicament is formulated: for intravitreal administration to a subject's eye; and to release the dexamethasone for at least about 4 months.

3. The pharmaceutical composition according to claim 1, or the use according to claim 2, wherein the dexamethasone comprises about 35 weight percent to about 45 weight percent of the pharmaceutical composition.

4. The pharmaceutical composition according to claim 1, or the use according to claim 2, wherein the biodegradable polymer matrix comprises: 85 ± 5 wt % of a biodegradable poly(D,L-lactide-co-glycolide) copolymer having an inherent

viscosity of 0.45 to 0.60 dL/g measured at 0.1% w/v in $CHCl_3$ at 25 °C with a Ubbelhode size 0c glass capillary viscometer.

5. The pharmaceutical composition according to claim 1, or the use according to claim 2, wherein the biodegradable polymer matrix comprises: 85 ± 5 wt % of a biodegradable poly(D,L-lactide-co-glycolide) copolymer having an inherent viscosity of 0.32-0.44 dL/g measured at 0.1% w/v in $CHCl_3$ at 25 °C with a Ubbelhode size 0c glass capillary viscometer.

6. An intravitreal implant for use in the treatment of an ocular disease, the intravitreal implant comprising the pharmaceutical composition of claim 1.

7. The intravitreal implant according to claim 6, wherein the intravitreal implant is to be administered to the vitreous humor of an eye of the human.

8. The intravitreal implant according to claim 6, wherein the ocular disease is macular edema, retinal vein occlusion, or uveitis.